Xgeva (Denosumab) 120 Mg Injection
Medical Evidence 
Generic nam e: Denosumab.
Trade name : Xgeva.
Manufacturer information :
Xgeva is manufactured by Amgen Inc.
Xgeva FDA Approval :
Xgeva first approved November 18th, 2010.
Xgeva Indication and Dosage form :
| Indication | Dosage form |
| Osteoporosis | Treatment of men and postmenopausal women with osteoporosis who are at high risk for fracture; treatment to Prolia: 60 mg SC every 6 monthsSupplement with calcium 1000 mg/day and vitamin D 400 IU/day. |
| Aromatase Inhibitor Induced Bone Loss | Women with breast cancer: 60 mg (Prolia) SC. |
| Androgen Deprivation Induced Bone Loss | Men with prostate cancer: 60 mg (Prolia) SC. |
| Skeletal-Related Events | 120 mg (1.7 mL). |
| Giant Cell Tumor | 120 mg SC. |
| Hypercalcemia of Malignancy | 120 mg SC. |
Xgeva (Denosumab) availability in India
- You could import this medicine against import permit on Patient Name.
- Please contact ACT Lifesciences Private Limited for further information.